Isabelle Sanchez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Isabelle Sanchez has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Rohaut
Sanofi, Oncology, in vivo Pharmacology, Vitry-Sur-Seine, France
78 shared publications - Christophe Marcireau
SANOFI, Vitry Sur Seine, France
78 shared publications - Frédéric Lacroix
Sanofi, Molecular Oncology, Vitry-sur-Seine, France
78 shared publications - Gilbert Thill
Sanofi, Translational Sciences, Chilly-Mazarin, France
78 shared publications - Hélène Erasimus
Sanofi, Molecular Oncology, Vitry-sur-Seine, France
78 shared publications - Laurent Debussche
Sanofi, Molecular Oncology, Vitry-sur-Seine, France
78 shared publications
Latest Publications
- Open Access
- 4 May 2023
- Published by American Association for Cancer Research (AACR)
Table S3 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
Table S3 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
- 4 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
Table S3 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
- Open Access
- 4 May 2023
- Published by American Association for Cancer Research (AACR)
Table S5 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
Table S5 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
- 4 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
Table S5 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
- Open Access
- 4 May 2023
- Published by American Association for Cancer Research (AACR)
Table S6 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
94 Putative synthetic lethal genes identified in the screen
- 4 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
94 Putative synthetic lethal genes identified in the screen
- Open Access
- 4 May 2023
- Published by American Association for Cancer Research (AACR)
Table S6 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
94 Putative synthetic lethal genes identified in the screen
- 4 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
94 Putative synthetic lethal genes identified in the screen
- Open Access
- 4 May 2023
- Published by American Association for Cancer Research (AACR)
Table S7 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
Table S7 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
- 4 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
Table S7 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
- Open Access
- 4 May 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
Construction and isolation of Cas9-expressing clones and workflow of our CRISPR screens. A, Levels of SMAD4 protein detected by the Sally Sue Simple Western system in the four cell lines HT29, SW620, DLD1, and MIAPaCa-2. B, Levels of Cas9 protein detected by the Sally Sue Simple Western system, in response to doxycycline treatment (exposure at 1 μg/mL for 3 days) in the four clones HT29, SW620, DLD1, and MIAPaCa-2 used in this study. C, Schematic representation of genome-wide CRISPR viability screens performed in HT29, SW620, DLD1, and MIAPaCa-2. Cells were infected at low MOI with a genome-wide library of sgRNAs. After selection, doxycycline was added to induce Cas9 and the KOs. Cells were regularly split and harvested, while keeping at least 200 million cells in culture to ensure a 1,000x library coverage. Cell growth curves of transduced cell lines following puromycin selection are plotted over time, for both replicates (circle and square). Arrows indicate samples that were harvested for sequencing at PD0 and PD15. sgRNA sequences were amplified and identified by NGS (NovaSeq). Enrichment/depletion of sgRNAS were assessed by comparing sgRNA counts at PD15 and PD0 using the Mageck analysis tool and by removing published core essential genes (Hart et al. 2017). PD, population doublings.
- 4 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
Construction and isolation of Cas9-expressing clones and workflow of our CRISPR screens. A, Levels of SMAD4 protein detected by the Sally Sue Simple Western system in the four cell lines HT29, SW620, DLD1, and MIAPaCa-2. B, Levels of Cas9 protein detected by the Sally Sue Simple Western system, in response to doxycycline treatment (exposure at 1 μg/mL for 3 days) in the four clones HT29, SW620, DLD1, and MIAPaCa-2 used in this study. C, Schematic representation of genome-wide CRISPR viability screens performed in HT29, SW620, DLD1, and MIAPaCa-2. Cells were infected at low MOI with a genome-wide library of sgRNAs. After selection, doxycycline was added to induce Cas9 and the KOs. Cells were regularly split and harvested, while keeping at least 200 million cells in culture to ensure a 1,000x library coverage. Cell growth curves of transduced cell lines following puromycin selection are plotted over time, for both replicates (circle and square). Arrows indicate samples that were harvested for sequencing at PD0 and PD15. sgRNA sequences were amplified and identified by NGS (NovaSeq). Enrichment/depletion of sgRNAS were assessed by comparing sgRNA counts at PD15 and PD0 using the Mageck analysis tool and by removing published core essential genes (Hart et al. 2017). PD, population doublings.
- Open Access
- 4 May 2023
- Published by American Association for Cancer Research (AACR)
Table S4 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
Table S4 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
- 4 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
Table S4 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
- Open Access
- 4 May 2023
- Published by American Association for Cancer Research (AACR)
Table S5 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
Table S5 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
- 4 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
Table S5 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
- Open Access
- 4 May 2023
- Published by American Association for Cancer Research (AACR)
Table S2 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
Table S2 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
- 4 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
Table S2 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
- Open Access
- 4 May 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
Table S1 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
- 4 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
Table S1 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss